


CLAIMS

What is claimed is:

1. A compound represented by Formula (I):



(I),

wherein:

Y^- is a pharmaceutically acceptable anion;

R^A , R^B , and R^C are each independently selected from H, D, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, OR^I , CN, CF_3 , $NR^J R^K$, $NR^L C(O)R^M$, $S(O)R^N$, $S(O)_2 R^N$, $SO_2 R^O R^P$, $SO_2 NR^Q R^R$, $SO_3 R^S$, $CO_2 R^T$, $C(O)R^U$, and $C(O)NR^V R^W$;

each of R^I , R^J , R^K , R^L , R^M , R^N , R^O , R^P , R^Q , R^R , R^S , R^T , R^U , R^V , and R^W is independently selected from H, D, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl; R^J and R^K or R^V and R^W or R^Q and R^R can also be taken together with the nitrogen to which they are attached to form a substituted or unsubstituted 5, 6, 7, or 8 membered ring; or

R^A , R^B , and/or R^C can be taken together with the phenyl ring to which they are attached can form a fused bicyclic or tricyclic ring system, such as naphthyl, dihydroindenyl, tetrahydronaphthyl, quinolinyl, indolyl;

R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 are independently selected from hydrogen, C_1 - C_4 alkyl, cycloalkyl, C_1 - C_4 heteroalkyl, aryl or heteroaryl, preferably hydrogen, methyl or ethyl;

or R_1 , R_2 , R_3 , R_4 , R_5 , and/or R_6 together with the carbon(s) to which they are attached form a substituted or unsubstituted cycloalkyl (such as a C_3 - C_6 cycloalkyl) or a substituted or unsubstituted heterocyclic (such as a 3- to 15-membered heterocyclic ring);

n is 0, 1, 2, 3, 4 and 5;

R^F and R^G together with the N^+ form an optionally substituted heterocyclic ring having, zero, one or more heteroatoms in addition to the N^+ , preferably 5, 6, 7, 8, or 9 ring members;

R^H is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl (such as $-CH_2$ -cycloalkyl, $-C_2H_4$ -cycloalkyl, substituted or unsubstituted $-CH_2-C_5-C_{10}$ aryl, substituted or unsubstituted $-C_2H_4-C_5-C_{10}$ aryl, substituted or unsubstituted $-CH_2-C_5-C_{10}$ heteroaryl, substituted or unsubstituted $-C_2H_4-C_5-C_{10}$ heteroaryl, $-CH_2 OC(O)R^T$, $-CH_2 CO_2R^T$, $-CH_2C(O)NR^VR^W$, $-C_2H_4OCOR^T$, $-C_2H_4OR^I$) or

R^F , R^G and R^H together with the N^+ form heteroaryl ring or bridged heterocyclic ring.

2. The compound of claim 1 wherein R^A is selected from H, methyl, halo (such as F, Cl or Br), CF_3 , CN, CO_2R^T , or OR^I , more preferably methyl, F, CF_3 or CN, most preferably methyl.

3. The compound of claim 1 or 2, wherein R^B is selected from H and methyl, preferably methyl.

4. The compound of any preceding claim, wherein R^C is selected from H, methyl, halo (such as F, Cl or Br), CF_3 , CN, CO_2R^T , or OR^I , more preferably H or OR^I , most preferably H.

5. The compound of any preceding claim, wherein each R_1 , R_2 , R_3 , R_4 , R_5 , and/or R_6 are hydrogen.

6. The compound of any one of claims 1-4, wherein R_1 is methyl or ethyl and R_2 , R_3 , R_4 , R_5 , and R_6 are hydrogen.


7. The compound of any one of claims 1-4, wherein R_3 is methyl or ethyl and R_1 , R_2 , R_4 , R_5 , and R_6 are hydrogen.

8. The compound of any preceding claim, wherein n is 0.

9. The compound of any preceding claim, wherein n is 1.

10. The compound of any preceding claim, wherein n is 3.

11. The compound of any preceding claim, wherein R^F and R^G together with the N^+ form a ring selected from a substituted or unsubstituted ring selected from:




and, most preferably,

10 Wherein R_7 is hydrogen or a substituted or unsubstituted alkyl.


12. The compound of claim 11, wherein the ring is unsubstituted.

13. The compound according to any preceding claim, wherein R^H is benzyl or substituted
15 benzyl, preferably benzyl.


14. The compound according to any one of claims 1 to 10, wherein R^F , R^G and R^H



15. The compound according to any preceding claim with the proviso that the compound is not:



16. A compound represented by Formula (I):



(II),

wherein:

Y^- is a pharmaceutically acceptable anion;

R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 are independently selected from hydrogen, C₁-C₄ alkyl, C₁-C₄ heteroalkyl, aryl or heteroaryl, preferably hydrogen, methyl or ethyl;

n is 0, 1, 2, 3, 4 and 5; and

q is 0, 1, 2, 3, 4 or 5.

17. The compound of claim 16, wherein q is 3.

18. The compound of claim 16 or 17, wherein R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 are hydrogen.

19. The compound of claim 16, wherein q is 2.

20. The compound of claim 19, wherein R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 are hydrogen.

21. The compound of claim 16, wherein q is 1.

22. The compound of claim 21, wherein R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 are hydrogen.

23. The compound of claim 16, wherein q is 0.

24. The compound of claim 23, wherein R₁, R₂, R₃, R₄, R₅, and R₆ are hydrogen.
25. The compound of claim 16, wherein R₁ is methyl R₂, R₃, R₄, R₅, and R₆ are
5 hydrogen.
26. The compound of claim 16, wherein R₃ is methyl R₁, R₂, R₄, R₅, and R₆ are
hydrogen.
- 10 27. The compound of any one of claims 16-26, wherein n is 0.
28. The compound of any one of claims 16-26, wherein n is 1.
29. The compound of any one of claims 16-26, wherein n is 2.
15
30. The compound of any one of claims 16-26, wherein n is 3.
31. The compound of any one of claims 16-26, wherein n is 4.
- 20 32. The compound of any one of claims 16-26, wherein n is 5.
33. The compound of any one of the preceding claims, wherein Y- is bromide or
chloride.
- 25 34. A pharmaceutical composition comprising the compound of any one of the preceding
claims and a pharmaceutically acceptable excipient.
35. The composition of claim 34, wherein said composition is formulated for topical or
dermal administration.
- 30 36. A method for treating itch, pain, cough, or a neurogenic inflammatory disorder in a
patient, comprising administering to said patient an effective amount of the
compound of any one of claims 1-33.

37. The method of claim 36, wherein said itch is selected from the group consisting of
itch due to pruritus, brachioradial pruritus, chronic idiopathic pruritus, genital/anal
pruritus, notalgia paresthetica, scalp pruritus, allergic dermatitis, contact dermatitis,
atopic dermatitis, hand eczema, poison ivy, infections, parasites, insect bites,
5 pregnancy, metabolic disorders, liver or renal failure, drug reactions, allergic
reactions, eczema, genital and anal itch, hemorrhoid itch, and cancer.